Theratechnologies Inc. (NASDAQ:THTX) Q1 2023 Earnings Conference Call April 12, 2023 8:30 AM ET

Company Participants

Elif McDonald - Head of Investor Relations

Paul Levesque - President and Chief Executive Officer

John Leasure - Global Commercial Officer

Philippe Dubuc - Chief Financial Officer

Christian Marsolais - Chief Medical Officer

Conference Call Participants

Louise Chen - Cantor

Justin Walsh - JonesTrading

Edward Nash - Canaccord Genuity

Endri Leno - National Bank

Operator

Good morning, ladies and gentlemen, and thank you for standing by. Welcome to Theratechnologies First Quarter Fiscal Year 2023 Earnings Call. We would like to remind everyone that all figures on this call are quoted in U.S. dollars.

At this time, all participants are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session with analysts. Instructions will be provided at that time for you to queue up for questions. Following the analyst Q&A session, investors wishing to submit a question may do so by clicking the "Ask a Question" link on the webcast platform. [Operator Instructions]

I would like to remind everyone that this conference call is being recorded today, Wednesday, April 12, 2023 at 08:30 A.M. Eastern Time.

I will now turn the call over to Ms. Elif McDonald, Head of Investor Relations. Ms. McDonald, please go ahead.

Elif McDonald

Thank you, Andrew, and good morning, everyone.

On the call today will be our President and Chief Executive Officer, Mr. Paul Levesque; and Chief Financial Officer, Mr. Philippe Dubuc; as well as our Global Commercial Officer, Mr. John Leasure. During our Q&A session, we will be joined by Dr. Christian Marsolais, our Chief Medical Officer.

Before we begin, I'd like to remind everyone that our remarks today contain forward-looking statements regarding our current and future plans, expectations and intentions with respect to future events. Forward-looking statements are based on assumptions and there are risks, that results obtained by Theratechnologies may differ materially from those statements. As such, the company cannot guarantee that any forward-looking statements will materialize and you are cautioned not to place undue reliance on them.

We refer current and potential investors to the forward-looking information and Risk Factors section of our management's discussion and analysis issued this morning and available on SEDAR at www.sedar.com and on EDGAR at sec.gov. Forward-looking statements represent Theratechnologies' expectations as of April 11, 2023.

Additionally, today, we are using the term adjusted EBITDA, which is in accordance with International Financial Reporting Standards, abbreviated as IFRS, or U.S. Generally Accepted Accounting Principles, abbreviated as U.S. GAAP. Adjusted EBITDA excludes the effects of items that are primarily reflect the impact of long-term investment and financing decisions rather than the results of day-to-day operations. Theratechnologies believes that this measure can be a useful indicator of its operational performance and financial condition from one period to another. The company uses this non-IFRS measure to make financial, strategic and operating decisions.